Hologic (HOLX) Q3 Revenue Beats 1%
(NASDAQ:HOLX), a global medical technology company specializing in diagnostics and women’s health, reported financial results for the third quarter of fiscal 2025 on July 30, 2025. The most notable headline: both GAAP revenue and non-GAAP earnings per share came in ahead of expectations, with GAAP revenue at $1,023.8 million compared to the $1,008.6 million analyst consensus, and non-GAAP earnings per share of $1.08 versus the $1.06 forecast. These figures beat both external analyst and company guidance (non-GAAP). The company continued to generate strong operating cash flow, though Organic revenue growth and margins faced headwinds in certain segments, particularly in Breast Health. Overall, Hologic posted a mixed quarter with clear outperforming areas, but underlying pressure in some key markets and business lines.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Hologic is a leading developer and manufacturer of medical devices and diagnostic products, with a core focus on women’s health. Its main business segments are Diagnostics, Breast Health, Surgical, and Skeletal Health.
Source Fool.com
Hologic Inc. Stock
Hologic Inc. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
As a result the target price of 81 € shows a positive potential of 39.66% compared to the current price of 58.0 € for Hologic Inc..
